About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Long Acting Neuraxial Peri-prostatic Block in Cancer

NCT06703437·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Icahn School of Medicine at Mount Sinai

Age

45–75

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

PSA \>10
PSAD \>0.15
PI-RADS 5 lesion on MRI
Karnofsky performance status \>80
Ability to understand and the willingness to sign a written informed consent.

You may not be if

Prior or concomitant treatment for prostate cancer, including radiation therapy, focal therapy, cryo therapy, androgen deprivation therapy.
Imaging or clinical evidence of metastatic disease.
PSA \> 100ng/mL

The record

StatusActive not recruiting

PhasePhase 1

Taking part12

StartedDec 2022

UpdatedSep 3, 2025

Conditions

Prostate Cancer

Where1

Icahn School of Medicine at Mount Sinai
New York, New York, United States

Clareo Health | Long Acting Neuraxial Peri-prostatic Block in Cancer